Company / PP&E (Net)
MBX Biosciences, Inc. PP&E (Net) History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$1.1M
FY2024
5-year range
$439.0K / $1.1M
FY2023-FY2024
Trend
+146.0%
vs FY2023
Sector context
#154 of 193
Health Care
What the data says
MBX Biosciences, Inc.'s pp&e (net) of $1M is lower than 80% of companies in the Health Care sector (FY2024).
Based on SEC 10-K filings.
$1M in FY2024.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 20% in Health CareTop 80% of 193This company $1.1M Sector average $777.6M
▼
-99.9% below sector average
Key checks
Key Insights
- In FY2024, pp&e (net) increased 146.0% year-over-year.
- Ranks #154 out of 193 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 9.64 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | $1.1M | +146.0% |
| FY2023 | $439.0K | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026